Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Immunogenicity and Efficacy Against Malaria in the Sporozoite Challenge Model of One Dose of Ad35.CS.01 Malaria Vaccine Followed by Two Doses of Malaria 257049 Vaccine in Healthy Malaria-naïve Adults

NCT01366534 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01366534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01366534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Immunogenicity and Efficacy Against Malaria in the Sporozoite Challenge Model of One Dose of Ad35.CS.01 Malaria Vaccine Followed by Two Doses of Malaria 257049 Vaccine in Healthy Malaria-naïve Adults
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
August 10, 2011
Completion date
July 3, 2012
Enrollment
67 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria